ImmunityBio
IBRX
149 hedge funds and large institutions have $200M invested in ImmunityBio in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 44 increasing their positions, 39 reducing their positions, and 20 closing their positions.
45% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 20
13% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 39
6% more funds holding
Funds holding: 141 → 149 (+8)
0.28% more ownership
Funds ownership: 8.67% → 8.95% (+0.28%)
5% less capital invested
Capital invested by funds: $209M → $200M (-$9.54M)
45% less call options, than puts
Call options by funds: $2.39M | Put options by funds: $4.31M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$3.93M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.34M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$2.45M |
| 4 |
Millennium Management
New York
|
+$2.04M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.9M |
Top Sellers
| 1 |
Renaissance Technologies
New York
|
-$1.85M |
| 2 |
Citigroup
New York
|
-$1.78M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.44M |
| 4 |
BlackRock
New York
|
-$1.4M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.13M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AGM
151
Alpine Global Management
New York
| – | -$90K | -14,805 | Closed |
|
|
LCM
152
Landscape Capital Management
Englewood,
New Jersey
| – | -$71K | -11,670 | Closed |
|
153
Dimensional Fund Advisors
Austin,
Texas
| – | -$62K | -10,221 | Closed |
|
|
FIA
154
FNY Investment Advisers
New York
| – | -$30.7K | -5,000 | Closed |
|
|
HFS
155
Hantz Financial Services
Southfield,
Michigan
| – | -$4K | -740 | Closed |
|
|
RWA
156
RGT Wealth Advisors
Dallas,
Texas
| – | -$1K | -200 | Closed |
|
|
QCG
157
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$1K | -145 | Closed |
|
158
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$1K | -100 | Closed |
|
|
C
159
Covestor
London,
United Kingdom
| – | -$92 | -15 | -18% |
|
|
SIC
160
SJS Investment Consulting
Sylvania,
Ohio
| – | +$6 | +1 | New |
|
|
DI
161
Disciplined Investments
Tulsa,
Oklahoma
| – | +$31 | +5 | New |
|
|
SC
162
Schubert & Co
Mckinney,
Texas
| – | +$31 | +5 | +167% |
|
|
JWA
163
JFS Wealth Advisors
Hermitage,
Pennsylvania
| – | +$74 | +12 | +171% |
|
|
CI
164
Cordant Inc
Portland,
Oregon
| – | +$80 | +13 | New |
|
IBRX Hedge Fund Activity: Q1 2022 in Review
149 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q1 2022, worth a combined $200M — down 4.6% from $209M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new IBRX positions and 20 closed out — a net gain of 9 holders — while 44 added to existing stakes and 39 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.93M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.85M sold.
- 149 institutional investors held ImmunityBio (IBRX) as of Q1 2022, up from 141 in Q4 2021.
- Funds reported $200M of ImmunityBio stock for Q1 2022, down 4.6% quarter-over-quarter.
- 29 funds opened new ImmunityBio positions in Q1 2022 and 20 closed out, a net change of +9 holders.
- The largest ImmunityBio buyer in Q1 2022 was Morgan Stanley, an estimated $3.93M added.
- The largest ImmunityBio seller in Q1 2022 was Renaissance Technologies, an estimated $1.85M sold.
Based on aggregated 13F filings for Q1 2022.